Genocea Biosciences
Feb 25, 2014

Genocea to Present at the Cowen and Company 34th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell enabled vaccines and immunotherapies, announced today that its president and chief executive officer, Chip Clark, will present a company overview at the Cowen and Company 34th Annual Health Care Conference. The presentation is scheduled for Monday, March 3, 2014 at 4:10 p.m. EST at the Boston Marriott Copley Place.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Genocea website at www.ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but are difficult to target using traditional discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea's pipeline of novel clinical stage T cell enabled vaccines includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. For more information, please visit the company's website at www.genocea.com.

For media:
Linnden Communications
Michelle Linn
O: 508-362-3087
M: 774-696-3803
Michelle@linndencom.com
or
For investors:
Genocea Biosciences
Bob Farrell
O: 617-674-8261
Bob.Farrell@genocea.com

 

Source: Genocea Biosciences, Inc.

News Provided by Acquire Media